Pricing

Adaptimmune Therapeutics Plc (ADAP)

followers ยท
Sector: HEALTH CARE
Industry: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO: Adrian Rawcliffe
Employees: 490
Web site: adaptimmune.com
60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, X0, OX14 4RX
44 1235 430000
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Adaptimmune Therapeutics plc focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS)
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available